BioSpace News Archive

Axcella today announced that it plans to report its second quarter 2021 financial results and other business updates on July 29, 2021. The company will host a conference call at 8:30 a.m. ET

IN8bio, Inc. today announced that it has launched an initial public offering of 4,000,000 shares of its common stock.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that management will participate in A.G.P.’s Virtual MedTech Summer Conference on Thursday, July 29, 2021.

Asylia Therapeutics, a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, announced the formation of a Scientific Advisory Board comprised of prominent experts and thought leaders in immunology and cancer biology.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2021 financial results before market open on Thursday, August 5, 2021.

VistaGen Therapeutics, Inc today announced the appointment of Maggie FitzPatrick to its Board of Directors (“Board”), replacing Dr. Brian J. Underdown who recently retired from the Board.

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on developing compounds to treat neurological conditions, is pleased to announce funding of its joint application with Dr. Argel Aguilar-Valles at Carleton University (“Carleton”) Department of Neuroscience by the Accelerate program at Mitacs for research into the anxiolytic potential of TD-010 in preclinical models of chronic anxiety and depression.

Kane Biotech Inc. announces plans to expand its wound care and surgical portfolio with an antimicrobial hydrogel based on its best-in-class coactiv+™ technology.

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing new classes of synthetic anti-infectives, is pleased to announce the United States (U.S.) Patent and Trademark Office has granted Patent Family 3 “Anti-Virus Agent and Method for Treatment Of Viral Infections,” furthering marketing and manufacturing monopolies to February 2037.

BioVie Inc. announced today that Poster 55458 entitled “ Rationale for an Anti-inflammatory Insulin Sensitizer in a Phase 3 Alzheimer’s Disease Trial” will be presented at the 2021 Alzheimer’s Association International Conference (AAIC), July 28, 2021.